PortfoliosLab logoPortfoliosLab logo
XENE vs. ANDE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

XENE vs. ANDE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xenon Pharmaceuticals Inc. (XENE) and The Andersons, Inc. (ANDE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, XENE achieves a 22.24% return, which is significantly lower than ANDE's 34.15% return. Over the past 10 years, XENE has outperformed ANDE with an annualized return of 24.15%, while ANDE has yielded a comparatively lower 9.88% annualized return.


XENE

1D
3.55%
1M
1.14%
YTD
22.24%
6M
18.90%
1Y
70.95%
3Y*
11.05%
5Y*
24.94%
10Y*
24.15%

ANDE

1D
-0.51%
1M
0.01%
YTD
34.15%
6M
30.40%
1Y
95.81%
3Y*
18.01%
5Y*
20.61%
10Y*
9.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

XENE vs. ANDE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
XENE
Xenon Pharmaceuticals Inc.
22.24%14.34%-14.89%16.81%26.22%103.12%17.32%107.77%123.36%-63.31%
ANDE
The Andersons, Inc.
34.15%33.82%-28.80%67.00%-7.77%61.48%0.81%-13.20%-2.10%-29.00%

Correlation

The correlation between XENE and ANDE is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.01

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (10Y)
Calculated over the trailing 10-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Nov 5, 2014

0.13

The correlation between XENE and ANDE shifts across timeframes, from 0.01 (1 year) to 0.17 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

XENE:

-$4.72

ANDE:

$5.02

Total Revenue (TTM)

XENE:

$0.00

ANDE:

$10.98B

Gross Profit (TTM)

XENE:

-$78.30M

ANDE:

$754.24M

EBITDA (TTM)

XENE:

-$399.62M

ANDE:

$272.26M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XENE vs. ANDE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XENE
XENE Risk / Return Rank: 8585
Overall Rank
XENE Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
XENE Sortino Ratio Rank: 9090
Sortino Ratio Rank
XENE Omega Ratio Rank: 8686
Omega Ratio Rank
XENE Calmar Ratio Rank: 8888
Calmar Ratio Rank
XENE Martin Ratio Rank: 8686
Martin Ratio Rank

ANDE
ANDE Risk / Return Rank: 9494
Overall Rank
ANDE Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
ANDE Sortino Ratio Rank: 9191
Sortino Ratio Rank
ANDE Omega Ratio Rank: 9292
Omega Ratio Rank
ANDE Calmar Ratio Rank: 9595
Calmar Ratio Rank
ANDE Martin Ratio Rank: 9696
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XENE vs. ANDE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xenon Pharmaceuticals Inc. (XENE) and The Andersons, Inc. (ANDE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


XENEANDEDifference
Sharpe ratioReturn per unit of total volatility

-1.63

Sortino ratioReturn per unit of downside risk

-0.07

Omega ratioGain probability vs. loss probability

1.35

1.46

-0.11

Calmar ratioReturn relative to maximum drawdown

3.88

6.84

-2.96

Martin ratioReturn relative to average drawdown

8.65

19.43

-10.79

XENE vs. ANDE - Sharpe Ratio Comparison

The current XENE Sharpe Ratio is 1.19, which is lower than the ANDE Sharpe Ratio of 2.82. The chart below compares the historical Sharpe Ratios of XENE and ANDE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

XENE vs. ANDE - Drawdown Comparison

The maximum XENE drawdown since its inception was -90.43%, which is greater than ANDE's maximum drawdown of -81.75%. Use the drawdown chart below to compare losses from any high point for XENE and ANDE.


Loading charts...

Drawdown Indicators


XENEANDEDifference

Max Drawdown

Largest peak-to-trough decline

-90.43%

-81.75%

-8.68%

Max Drawdown (1Y)

Largest decline over 1 year

-18.40%

-14.09%

-4.31%

Max Drawdown (3Y)

Largest decline over 3 years

-43.59%

-46.94%

+3.35%

Max Drawdown (5Y)

Largest decline over 5 years

-43.59%

-48.82%

+5.23%

Max Drawdown (10Y)

Largest decline over 10 years

-77.66%

-72.72%

-4.94%

Current Drawdown

Current decline from peak

-12.70%

-10.78%

-1.92%

Average Drawdown

Average peak-to-trough decline

-39.42%

-32.29%

-7.13%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.23%

4.95%

+3.28%

Volatility

XENE vs. ANDE - Volatility Comparison

The current volatility for Xenon Pharmaceuticals Inc. (XENE) is 8.27%, while The Andersons, Inc. (ANDE) has a volatility of 8.87%. This indicates that XENE experiences smaller price fluctuations and is considered to be less risky than ANDE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XENEANDEDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.27%

8.87%

-0.60%

Volatility (6M)

Calculated over the trailing 6-month period

46.47%

25.13%

+21.34%

Volatility (1Y)

Calculated over the trailing 1-year period

59.90%

34.18%

+25.72%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.60%

38.88%

+28.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

66.41%

41.55%

+24.86%

Dividends

XENE vs. ANDE - Dividend Comparison

XENE has not paid dividends to shareholders, while ANDE's dividend yield for the trailing twelve months is around 1.11%.


PositionTTM20252024202320222021202020192018201720162015
ANDE
The Andersons, Inc.
1.11%1.47%1.41%1.29%2.07%1.82%2.86%2.71%2.22%2.07%1.40%1.82%
XENE
Xenon Pharmaceuticals Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

XENE vs. ANDE - Financials Comparison

This section allows you to compare key financial metrics between Xenon Pharmaceuticals Inc. and The Andersons, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B202220232024202520260
2.63B
(XENE) Total Revenue
(ANDE) Total Revenue
Values in USD except per share items

Frequently Asked Questions


XENE and ANDE have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ANDE has higher volatility (8.87%) compared to XENE (8.27%). In terms of maximum drawdown, XENE dropped -90.43% vs ANDE's -81.75%.

ANDE currently has the higher Sharpe Ratio (2.82 vs 1.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for XENE and ANDE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer